pyrazines has been researched along with Viremia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Feldmann, F; Feldmann, H; Furuta, Y; Gowen, BB; Haddock, E; Hanley, PW; Hawman, DW; Komeno, T; Lovaglio, J; Meade-White, K; Nakajima, N; Nardone, G; Scott, D | 1 |
| Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Mashima, D; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y | 1 |
| Baillet, N; Baize, S; de Lamballerie, X; Gloaguen, E; Guedj, J; Madelain, V; Mullaert, J; Raoul, H; Reynard, S | 1 |
| Akondy, RS; Cannon, D; Ellebedy, AH; Harmon, JR; Klena, JD; Kraft, CS; Lyon, MG; McElroy, AK; Mehta, AK; Nichol, ST; Ribner, BS; Sette, A; Sidney, J; Spiropoulou, CF; Varkey, JB | 1 |
| Bavari, S; Chitty, AJ; Espy, N; Garcia, K; Nagle, E; Palacios, G; Pfeffer, B; Sanchez-Lockhart, M; Warren, T; Wiley, M | 1 |
| Brasel, T; Freiberg, AN; Furuta, Y; Gowen, BB; Hill, TE; Juelich, TL; Pietzsch, C; Sefing, EJ; Smith, JK; Tigabu, B; Yun, T; Zhang, L | 1 |
| Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M | 1 |
7 other study(ies) available for pyrazines and Viremia
| Article | Year |
|---|---|
Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques.
Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Schedule; Female; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Macaca fascicularis; Male; Pyrazines; Viral Load; Viremia; Virus Shedding | 2020 |
A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Nasopharynx; Nucleic Acid Amplification Techniques; Pneumonia, Viral; Pyrazines; Respiration, Artificial; RNA, Viral; SARS-CoV-2; Treatment Outcome; Viremia | 2021 |
Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.
Topics: Amides; Animals; Antiviral Agents; Cytokine Release Syndrome; Cytokines; Disease Models, Animal; Ebolavirus; Hemorrhagic Fever, Ebola; Macaca fascicularis; Pyrazines; T-Lymphocytes; Viral Load; Viremia; Virus Replication | 2021 |
A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.
Topics: Adult; Amides; Antibodies, Viral; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunity, Cellular; Immunoglobulin Class Switching; Lassa Fever; Lassa virus; Lymphocyte Activation; Male; Pyrazines; Ribavirin; Viremia | 2017 |
T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques.
Topics: Amides; Animals; Antiviral Agents; DNA, Viral; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Macaca; Male; Marburg Virus Disease; Marburgvirus; Mutagenesis; Pyrazines; Viremia | 2019 |
Favipiravir (T-705) inhibits JunÃn virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.
Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Disease Models, Animal; Guinea Pigs; Hemorrhagic Fever, American; Injections, Intraperitoneal; Junin virus; Male; Plasma; Pyrazines; Survival Analysis; Viremia | 2013 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation | 2012 |